<?xml version="1.0" encoding="UTF-8"?>
<p>Conditioning comprised busulfan (0.8 mg/kg twice daily IV) and fludarabine (30 mg/m
 <sup>2</sup> once daily IV) from days −5 to −2. T-replete donor peripheral blood stem cells (PBSC) dosed at ≥ 2×10
 <sup>6</sup> CD34
 <sup>+</sup> cells/kg were infused on day 0. GvHD prophylaxis regimens were: tac/mtx (arm A), bort/tac/mtx (arm B), and bort/sir/tac (arm C). Dosing was: bort (1.3 mg/m
 <sup>2</sup> IV on day +1, +4, +7), mtx (10 mg/m
 <sup>2</sup> IV on day +1, 5 mg/m
 <sup>2</sup> on day +3, +6, +11), sir (target trough level 5–12 ng/ml) and/or tac (target trough level 5–10 ng/ml) from day −3. The tapering of immunosuppression started at around d+100, with the aim of being off immune suppression (IS) by day +180, as applicable per treatment arm.
</p>
